FRI0607 Long-term and optimization of infliximab in refractory uveitis associated to behÇet disease. multicentre study of 100 patients. (15th June 2017)

• Record Type: Journal Article
• Authors: Casas, LC Domínguez; Calvo-Río, V; Beltrán, E; S-Bursόn, J; Mesquida, M; Adán, A; Hernandez, M; L-Longo, F; H-Grafella, M; Valls, E; M-Costa, L; Sellas, A; G-Serrano, J; Callejas, J; Ortego, N; Herreras, J; Follonosa, A; Maíz, O; Blanco, A; Torre, I; F-Espartero, C; Jovani, V; Peitado, D; Díaz-Valle, D; Pato, E; F-Cid, C; Aurrecoechea, E; García, M; Caracuel, M; Atanes, A; Francisco, F; Insua, S; González-Suárez, S; S-Andrade, A; Linares, L; Romero, F; García, A; Almodovar, R; Minguez, E; Carrasco, C; Raya, E; Alcalde, M; F-Carballido, C; Pagés, F; González-Vela, M; Fernández-Díaz, C; Vegas-Revenga, N; Demetrio-Pablo, R; González-Gay, M; Blanco, R;
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 718
• Page End: 719
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.6226
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: To assess the long term efficacy and optimization of Infliximab (IFX) in refractory Uveitis of Behçet Disease (BD) Methods: Multicentre study of Uveitis associated-BD refractory to conventional immunosupressive drug. Ocular inflammation was evaluated with "SUN criteria" (Am J Ophthalmol 2005;140:509–516) and the macular thickening with OCT. Results are expressed as mean±SD or median [IQR] (comparison, Wilcoxon test) Results: We studied 100 patients/180 affected eyes (54M/46W), mean age 40.7±10.1. The ocular pattern was panuveitis (n=62), posterior (27) and anterior uveítis (11). Before IFX they received iv MP (28), cyclosporine (75), azathioprine (56), metotrexate (43) and others (33). IFX dose ranged between 3–5mg/kg/4 or 8 weeks. In patients in remission IFX was optimized (n=28) or stopped (n=20). Conclusions: IFX is an effective long term-treatment in refractory Uveitis of BD. Optimization and even discontinuation of IFX after remission is possible. Disclosure of Interest: None declared